

# Low molecular weight heparin in pregnancies with persistently abnormal uterine artery Doppler, does it make a difference? A prospective proof of concept study

Eman Aly Abd El Fattah  $^{1,\ast}$ 

<sup>1</sup> Department of Obstetrics and Gynecology, Alexandria University, Faculty of Medicine, Shatby Maternity Hospital, 21526 Alexandria, Egypt \*Correspondence: emanoemanoeman7@Gmail.com; emanaly91171@gmail.com (Eman Aly Abd El Fattah)

DOI:10.31083/j.ceog.2021.02.2311

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). Submitted: 29 September 2020 Revised: 20 January 2021 Accepted: 22 January 2021 Published: 15 April 2021

Introduction: Trophoblastic invasion converts the uteroplacental circulation into a low resistance, high capacitance system. Defective invasion causes hypoperfusion and pregnancy complications. Early pregnancy uterine artery Doppler demonstrates low end-diastolic velocities. Its PI and RI decrease with increasing gestation. Aim of the study: Examing the effect of adding low molecular weight heparin (LMWH) to low-dose aspirin on persistent high uterine artery Doppler indices and its impact on fetal growth and pregnancy outcome. Patients and methods: After approval of Alexandria university ethics committee, pregnant cases with positive past history of placental vascular complication including; placental abruption, preeclampsia, small-for-gestational age (SGA) pregnancies and fetal growth restriction were recruited. All selected patients were in good general health without previous history of Diabetes Mellitus or thyroid disorders or cardiac diseases. Patients with thrombocytopenia, bleeding tendencies, multiple pregnancies, and pregnancies complicated by fetal or neonatal chromosomal or structural anomalies were excluded from the study. Eligible patients were 412, all were subjected to uterine artery Doppler measurement in the first trimester. 148 cases had high uterine artery Doppler PI, they were given low dose aspirin and were re-evaluated at 22--24 weeks gestation. 58 cases had persistently high uterine artery Doppler PI, they were allocated into 2 groups each of 29 cases; Group A LMWH with aspirin. Group B only low dose aspirin. 50 pregnants with normal uterine artery Doppler PI from the start were taken as a control group. All participants were followed up at 28--30 and 34--36 weeks. Primary outcome: Normal uterine, umbilical and cerebral artery Doppler measurements after LMWH. Secondary outcome: Prevention of pregnancy complications and neonatal complications. Results: Uterine and umbilical artery Doppler and amount of liquor significantly improved. Conclusion: LMWH influenced uterine artery and umbilical Doppler measurements and amount of liquor and reduced the risk of neonatal hypoxic ischaemic encephalopathy.

#### Keywords

LMWH; Uterine Doppler; Umbilical Doppler; Oligohydramnios

#### 1. Introduction

The placenta is important for the transport of nutrients and oxygen to the fetus. Placental remodeling occurs in two stages; the first stage starts in the first trimester, when the trophoblastic cells invade the intra-decidual portion of the spiral arteries then they deeply invade the myometrial segments of the spiral arteries from 14 weeks' gestation causing loss of smooth muscle and elastica from the spiral arteries converting the uteroplacental circulation into a low resistance, high capacitance system [1, 2]. The second stage of placental remodeling is completed between 16 to 18 weeks gestation. Defective placental implantation leads to hypoperfusion, hypoxic reperfusion injury, and oxidative stress which is thought to underlie the pathophysiology of gestational hypertension, preeclampsia (PE), intra-uterine fetal growth restriction (IUGR), preterm labor, placental abruption, and second-trimester miscarriages [3, 4].

In the nonpregnant state and in early pregnancy, Doppler interrogation of the uterine artery demonstrates low enddiastolic velocities and an early diastolic notch. Uterine artery PI and RI values decrease with increasing gestational age due to a fall in impedance in uterine vessels following trophoblastic invasion. Resistance to blood flow within the uteroplacental circulation is transmitted upstream to the uterine arteries and can be measured as an increased pulsatility index (PI) or resistance index [5–7].

Improvements in uterine blood flow following low-dose aspirin or low molecular weight heparin (LMWH) administration has been reported to improve pregnancy outcomes particularly in those patients with decreased uterine blood flow and poor obstetric histories, such as recurrent pregnancy loss (RPL) or antiphospholipid antibody syndrome (APS) [8, 9].

In this study we aimed to examine the effect of adding low molecular weight heparin (LMWH) to aspirin on the flow velocity of uterine and umbilical arteries in cases with persistently high uterine artery Doppler, on fetal growth and pregnancy outcome.

#### 2. Materials and methods

The study was approved by ethics committee of the Alexandria faculty of the college of medicine. Informed consent was obtained prior to the initiation of the study. Cases with positive past history of placental vascular complication including placental abruption, pre-eclampsia, small-for-gestational age (SGA) and fetal growth restriction were recruited from the ANC clinic. None of the patients had a past history of diabetes mellitus, thyroid disorders or cardiac disease. Cases of thrombophilia, thrombocytopenia, bleeding tendencies, multiple gestation, and pregnancies complicated by fetal or neonatal chromosomal or structural anomalies were excluded.

Uterine artery Doppler assessment was done in the first trimester by a transvaginal ultrasound technique using a 4.6– 8 MHz transvaginal transducer placed in the anterior vaginal fornix, where a sagittal section of the cervix was obtained. The probe was moved laterally until the paracervical vascular plexus was identified. Color flow Doppler was applied and the uterine artery was identified at the level of the cervicouterine junction. Measurements were taken at the point before the uterine artery branches into the arcuate arteries.

Cases identified with high uterine artery Doppler PI were administered low dose aspirin 75 mg tablets daily (Ezacard, Global Nabi, Egypt) and were re-evaluated in the second trimester (22-24 weeks of gestation) by a transabdominal approach where a 3.5-MHz curvilinear transabdominal transducer was used. A midsagittal section of the uterus and cervical canal was obtained and the transducer was moved laterally until the paracervical vessels were visualized. Color flow Doppler was applied. The uterine arteries were visualized along the side of the cervix. Pulsed wave Doppler flow velocity waveforms from the ascending branch of the uterine artery at the point closest to the internal os were obtained, with the Doppler sampling gate set at 2 mm. The smallest angle of insonation ( $< 30^{\circ}$ ) was used in order to achieve the highest systolic and end-diastolic velocities. When three similar consecutive waveforms were obtained, the pulsatility index (PI) was measured. The mean PI was calculated as the average reading from each side combined. A mean  $PI \ge 95$ th percentile for gestational age was considered abnormal. Reference ranges utilized were those presented by Olga Gomez et al. [10, 11] Table 1.

Cases with persistent high uterine artery Doppler PI were allocated into 2 groups. Allocation was performed at random by an independent statistician using a shuffled deck of cards (odd numbers for Group A, even-numbers for Group B) to equilize the 2 arms among subjects.

**Group** A were given low molecular weight heparin (LMWH) [enoxaparin sodium (clexane 40 mg/0.4 mL Syringes), Sanofi Aventis, France] addition to the aspirin. The LMWH was administered each evening by a subcutaneous abdominal injection.

Group B received low dose aspirin alone.


These two groups were compared to a control group of 50 patients with normal uterine artery Doppler PI.


All groups were followed up at 28–30 and 34–36 weeks gestation. Measurements obtained were for uterine artery Doppler, umbilical artery Doppler, cerebral artery Doppler,

 Table 1. Mean PI reference range according to gestational

| age.       |                  |                   |                          |  |  |
|------------|------------------|-------------------|--------------------------|--|--|
| GA (weeks) | $5^{th}$ centile | $50^{th}$ centile | 95 <sup>th</sup> centile |  |  |
| 11         | 1.18             | 1.79              | 2.70                     |  |  |
| 12         | 1.11             | 1.68              | 2.53                     |  |  |
| 13         | 1.05             | 1.58              | 2.38                     |  |  |
| 14         | 0.99             | 1.49              | 2.24                     |  |  |
| 15         | 0.94             | 1.41              | 2.11                     |  |  |
| 16         | 0.89             | 1.33              | 1.99                     |  |  |
| 17         | 0.85             | 1.27              | 1.88                     |  |  |
| 18         | 0.81             | 1.20              | 1.79                     |  |  |
| 19         | 0.78             | 1.15              | 1.70                     |  |  |
| 20         | 0.74             | 1.10              | 1.61                     |  |  |
| 21         | 0.71             | 1.05              | 1.54                     |  |  |
| 22         | 0.69             | 1.00              | 1.47                     |  |  |
| 23         | 0.66             | 0.96              | 1.41                     |  |  |
| 24         | 0.64             | 0.93              | 1.35                     |  |  |
| 25         | 0.62             | 0.89              | 1.30                     |  |  |
| 26         | 0.60             | 0.86              | 1.25                     |  |  |
| 27         | 0.58             | 0.84              | 1.21                     |  |  |
| 28         | 0.56             | 0.81              | 1.17                     |  |  |
| 29         | 0.55             | 0.79              | 1.13                     |  |  |
| 30         | 0.54             | 0.77              | 1.10                     |  |  |
| 31         | 0.52             | 0.75              | 1.06                     |  |  |
| 32         | 0.51             | 0.73              | 1.04                     |  |  |
| 33         | 0.50             | 0.71              | 1.01                     |  |  |
| 34         | 0.50             | 0.70              | 0.99                     |  |  |
| 35         | 0.49             | 0.69              | 0.97                     |  |  |
| 36         | 0.48             | 0.68              | 0.95                     |  |  |
| 37         | 0.48             | 0.67              | 0.94                     |  |  |
| 38         | 0.47             | 0.66              | 0.92                     |  |  |
| 39         | 0.47             | 0.65              | 0.91                     |  |  |
| 40         | 0.47             | 0.65              | 0.90                     |  |  |
| 41         | 0.47             | 0.65              | 0.89                     |  |  |

estimated fetal weight utilizing biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL) [12] and amniotic fluid index (AFI). Normal AFI values ranged from 5 to 25 cm [13-16]. Cases were assessed for development of pregnancy complications such as preeclampsia, intrauterine growth restriction (IUGR) and preterm labor. Preeclampsia was defined according to the guidelines of the International Society for the Study of Hypertension in Pregnancy as blood pressure at least 140/90 mmHg on two occasions at least 4 hours apart with 300 mg or more proteinuria during 24 hours after 20 weeks gestation [17]. IUGR was diagnosed if the estimated fetal weight was below the 10th percentile for gestational age together with a Doppler PI in the umbilical artery above the 95th percentile, or if the estimated fetal weight was below the 3rd percentile irrespective of the umbilical artery Doppler [18]. Preterm delivery was defined as delivery before 37 weeks of gestation. All pregnant women received routine antenatal care and were followed until delivery (Table 2).





**Primary outcome**: normalization of uterine, umbilical and cerebral artery Doppler measurements after LMWH.

Secondary outcome: prevention of pregnancy and neonatal complications.

After delivery, neonatal outcome was assessed and Apgar scores and admission to the neonatology unit were recorded.

## 3. Statistical analysis

Statistical analysis was done using Statistical Package for Social Sciences (SPSS/version 21) software. Arithematic mean, standard deviation, number and percent were obtained. For categorized parameters, chi square test was used while for numerical data ANOVA-test was utilized to compare more than two groups. The level of significance was 0.05.

### 4. Results

We recruited 412 cases with a positive past history of placental vascular complication in previous pregnancies. During the initial prenatal visit in the first trimester, 148 cases had high uterine artery Doppler PI. They were administered low dose aspirin and were re-evaluated during the second trimester. The uterine artery Doppler measurements reverted to normal in 90 cases while the remaining 58 cases had persistently high uterine artery Doppler PI. They were blindly allocated into 2 groups each having 29 cases. Allocation was performed at random by an independent statistician using a shuffled deck of cards (odd numbers for Group A, even-numbers for Group B) to equilize the 2 arms among subjects.

Group A received low molecular weight heparin with low dose aspirin while Group B continued low dose aspirin alone. Group A and B were compared to a control group of 50 cases with a similar past history but with normal uterine artery Doppler.

#### 4.1 Demographic data

The three groups had no significant differences as related to demographic data and duration from the last pregnancy (Table 3).

#### 4.2 Uterine artery Doppler measurements

Uterine artery Doppler measurements during the third trimester were statistically significant among the groups  $[P = 0.018^*]$ . Only one case in Group A had persistently high uterine artery Doppler PI compared to four cases in Group B. In the control group, uterine artery Doppler PI measurements remained normal throughout the pregnancy (Table 4, Fig. 1).




Fig. 1. Comparison between the three studied groups regarding third trimester uterine Doppler PI.

#### 4.3 Umbilical artery Doppler measurements

Umbilical artery Doppler measurements were statistically significant among the three groups [P = 0.034]. In Group A, the same patient with the abnormal artery Doppler also had an elevated S/D ratio. In Group B, six cases had abnormal umbilical artery Doppler measurements; three of them were the same cases with abnormal uterine artery Doppler, and the other three had normal uterine Doppler. One case with an abnormal uterine artery Doppler had absent end diastolic flow. In the control group, only one case had an elevated S/D ratio (Table 5, Fig. 2).

#### 4.4 Cerebral artery Doppler measurements

Cerebral artery Doppler measurements although were not statistically significant among the three groups [P = 0.251]. There were no abnormal cases in Group A but two cases of abnormal cerebral artery Doppler occurred in Group B both with fetal growth restriction. These 2 patients had abnormal uterine artery Doppler, abnormal umbilical artery Doppler and one case with absent umbilical end diastolic flow. Both had oligohydramnios and developed preeclampsia (PET). They were delivered at 31–33 weeks gestation with both neonates developing signs of hypoxic ischaemic encephalopathy. No cases of abnormal cerebral artery Doppler were found in the control group (Table 6).

|                                  | Group A (Heparin gp) | Group B (Aspirin only group) | Group C (Control group) | ANOVA      |  |
|----------------------------------|----------------------|------------------------------|-------------------------|------------|--|
|                                  | Gloup A (Hepathi gp) | Group B (Aspirin only group) | Group C (Control group) | P-value    |  |
| Age                              |                      |                              |                         |            |  |
| Range                            | 23.0-32.0            | 21.0-33.0                    | 22.0-31.0               |            |  |
| Mean                             | 28.4                 | 27.6                         | 27.4                    | 1.088      |  |
| S.D.                             | 3                    | 3.9                          | 2.7                     | 0.341 N.S. |  |
| BMI                              |                      |                              |                         |            |  |
| Range                            | 23.5-31.0            | 23.6-31.5                    | 23.0-30.4               |            |  |
| Mean                             | 27.1                 | 27.4                         | 26.9                    | 0.469      |  |
| S.D.                             | 2.2                  | 2.4                          | 2.4                     | 0.627 N.S. |  |
| Duration from the last pregnancy |                      |                              |                         |            |  |
| Range                            | 1.2-4.8              | 1.3-4.5                      | 1.1-4.8                 |            |  |
| Mean                             | 2.9                  | 3.1                          | 2.9                     | 0.317      |  |
| S.D.                             | 1                    | 1                            | 1.3                     | 0.729 N.S. |  |

Table 3. Comparison between the three studied groups regarding basic demographic data.

P was significant if  $\leq$  0.05. N.S., Not significant.

| Table 4. Comparison between the | three studied groups reg | arding third trimester | uterine Doppler PI. |
|---------------------------------|--------------------------|------------------------|---------------------|
|                                 |                          |                        |                     |

| Third trimester uterine Doppler PI |                      | Group                                             |        |                         |        |  |
|------------------------------------|----------------------|---------------------------------------------------|--------|-------------------------|--------|--|
| i ill'a triffeste                  | a diernie Doppier Pr | Group A (Heparin gp) Group B (Aspirin only group) |        | Group C (Control group) | Total  |  |
| Normal                             | No.                  | 28                                                | 25     | 50                      | 103    |  |
|                                    | %                    | 96.6%                                             | 86.2%  | 100.0%                  | 95.4%  |  |
| High                               | No.                  | 1                                                 | 4      | 0                       | 5      |  |
|                                    | %                    | 3.4%                                              | 13.8%  | 0.0%                    | 4.6%   |  |
| Total                              | No.                  | 29                                                | 29     | 50                      | 108    |  |
|                                    | %                    | 100.0%                                            | 100.0% | 100.0%                  | 100.0% |  |
| $X^2$                              |                      |                                                   | 8.034  |                         |        |  |
| Р                                  |                      |                                                   | 0.018* |                         |        |  |

 $X^2$  = Chi square test. *P* was significant if  $\leq$  0.05. \* = significant difference.




Fig. 2. Comparison between the three studied groups regarding umbilical Doppler.




Fig. 3. Comparison between the three studied groups regarding oligohydramnios.

#### 4.5 Obstetric complications

Obstetric complications encountered were *oligohy- draminos, PET, IUGR and preterm labor.* 

**Oligohydramnios** was present in one case from Group A compared to four cases in Group B (two cases with IUGR and two with abnormal uterine and umbilical arteries Doppler. No cases of oligohydramnios were found in the control group which was statistically significant [P = 0.018] (Table 7, Fig. 3).

As regards Preeclamptic toxemia (PET), no cases were found in Group A compared to the two cases with IUGR in Group B (4.4) and one case in the control group. This result was not statistically significant [P = 0.251] (Table 8).

**IUGR**: one case of IUGR in Group A compared to three cases in Group B. No cases IUGR occurred in the control group. These results were not statistically significant [P = 0.221] (Table 9).

| Umbilical Doppler  |     | Group                |                              |                         |        |
|--------------------|-----|----------------------|------------------------------|-------------------------|--------|
| Onibilical Dopplet |     | Group A (Heparin gp) | Group B (Aspirin only group) | Group C (Control group) | Total  |
| Normal             | No. | 28                   | 23                           | 49                      | 103    |
|                    | %   | 96.6%                | 79.3%                        | 98.0%                   | 95.4%  |
| Abnormal           | No. | 1                    | 6                            | 1                       | 8      |
|                    | %   | 3.4%                 | 20.6%                        | 2.0%                    | 7.4%   |
| Total              | No. | 29                   | 29                           | 50                      | 108    |
|                    | %   | 100.0%               | 100.0%                       | 100.0%                  | 100.0% |
| $X^2$              |     |                      | 6.25                         |                         |        |
| Р                  |     |                      | 0.034*                       |                         |        |

Table 5. Comparison between the three studied groups regarding umbilical Doppler.

 $X^2$  = Chi square test. *P* was significant if  $\leq$  0.05. N.S., Not significant.

| Table 6. Comparison between the three studied | groups regarding cerebral artery Doppler. |
|-----------------------------------------------|-------------------------------------------|
| Table 0. Comparison between the three studied | groups regarding cerebrar artery Doppier. |

|     | Group                                                             |                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                        |  |
|-----|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|     | Group A (Heparin gp) Group B (Aspirin only group) Group C (Contro |                                                                                                                     | Group C (Control group)                                                                                                                                                                                                                                                                                                                                                                                         | oup) Total                                                                                                                                                                                                                                                                                                                                                                                             |  |
| No. | 29                                                                | 27                                                                                                                  | 49                                                                                                                                                                                                                                                                                                                                                                                                              | 105                                                                                                                                                                                                                                                                                                                                                                                                    |  |
| %   | 100.0%                                                            | 93.1%                                                                                                               | 98.0%                                                                                                                                                                                                                                                                                                                                                                                                           | 97.2%                                                                                                                                                                                                                                                                                                                                                                                                  |  |
| No. | 0                                                                 | 2                                                                                                                   | 0                                                                                                                                                                                                                                                                                                                                                                                                               | 2                                                                                                                                                                                                                                                                                                                                                                                                      |  |
| %   | 0.0%                                                              | 6.9%                                                                                                                | 0.0%                                                                                                                                                                                                                                                                                                                                                                                                            | 1.9%                                                                                                                                                                                                                                                                                                                                                                                                   |  |
| No. | 29                                                                | 29                                                                                                                  | 50                                                                                                                                                                                                                                                                                                                                                                                                              | 108                                                                                                                                                                                                                                                                                                                                                                                                    |  |
| %   | 100.0%                                                            | 100.0%                                                                                                              | 100.0%                                                                                                                                                                                                                                                                                                                                                                                                          | 100.0%                                                                                                                                                                                                                                                                                                                                                                                                 |  |
|     |                                                                   | 2.762                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                        |  |
|     |                                                                   | 0.251                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                        |  |
|     | %<br>No.<br>%<br>No.                                              | No.         29           %         100.0%           No.         0           %         0.0%           No.         29 | Group A (Heparin gp)         Group B (Aspirin only group)           No.         29         27           %         100.0%         93.1%           No.         0         2           %         0.0%         6.9%           No.         29         29           %         0.0%         6.9%           No.         29         29           %         100.0%         100.0%           %         100.0%         2.762 | Group A (Heparin gp)         Group B (Aspirin only group)         Group C (Control group)           No.         29         27         49           %         100.0%         93.1%         98.0%           No.         0         2         0           %         0.0%         6.9%         0.0%           No.         29         29         50           %         100.0%         100.0%         100.0% |  |

 $X^2$  = Chi square test. *P* was significant if  $\leq$  0.05. N.S., Not significant.

**Preterm labor** was more common in Group B; three cases delivered prematurely possibly because of PET and IUGR and case secondary to preterm premature rupture of the membranes. One case in Group A due to IUGR and oligohydramnios with no cases in the control group. These results did not reach statistical significance [P = 0.063] (Table 10).

# 4.6 Neonates

All neonates were discharged except for one case in Group A due to respiratory distress and two cases in Group B due to IUGR and hypoxic ischaemic encephalopathy. There were no cases in the control group. This result was not statistically significant [P = 0.253] (Table 11).

## 5. Discussion

Low molecular weight heparin (LMWH) used in pregnancy has been proven to reverse the natural antiangiogenic tendency of first-trimester placental villi [19]. It has been evaluated for the prevention of various placenta-mediated pregnancy complications, including severe preeclampsia and recurrent miscarriage.

In our study, cases using LMWH had statistically significant normal measurements of uterine artery, which was reflected in the course of pregnancy as related to amount of amniotic fluid. Early effects probably occur at the cellular level by decreasing trophoblast apoptosis.

Effect on performance of uterine artery Doppler has been investigated in many trials.

In 2006, researchers performed a controlled, open-labeled

study which included 94 women with gestational hypertension and 30 healthy women enrolled at 24 to 26 weeks gestation. Doppler evaluation of uterine artery resistance index (RI) was performed before and after a two-week course of LMWH or no treatment. This study investigated whether a short course of subcutaneous low-molecular-weight heparin (LMWH) might modify the performance of uterine artery Doppler to predict preeclampsia and small-for-gestational age (SGA) infants in a high-risk population. The authors found a significant decrease of uterine artery RI after LMWH (P < 0.001, paired Student's *t*-test), whereas the untreated hypertensive patients and the healthy control group showed no change between the two Doppler evaluations [20].

These results match with ours as adding LMWH to aspirin reduced the high uterine artery Doppler PI.

A randomized controlled trial included 139 women with inheritable thrombophilia seen prior to 12 weeks of gestation with a history of previous delivery before 34 weeks of gestation secondary to hypertensive disorders of pregnancy and/or small-for-gestational-age infants. Women were randomized to receive either daily LMWH with aspirin or aspirin only and they followed with flow velocity within the uterine and umbilical arteries as well as evaluation of fetal growth. They found that addition of LMWH to aspirin did not influence fetal growth, nor did it influence uterine artery or umbilical artery flow velocity [21].

| Oligohydramnio     | c.  | Group                |                              |                         |        |
|--------------------|-----|----------------------|------------------------------|-------------------------|--------|
| Oligoliyuraliililo | 5   | Group A (Heparin gp) | Group B (Aspirin only group) | Group C (Control group) | Total  |
| Absent             | No. | 28                   | 25                           | 50                      | 103    |
|                    | %   | 96.6%                | 86.2%                        | 100.0%                  | 95.4%  |
| Present            | No. | 1                    | 4                            | 0                       | 5      |
|                    | %   | 3.4%                 | 13.8%                        | 0.0%                    | 4.6%   |
| Total              | No. | 29                   | 29                           | 50                      | 108    |
|                    | %   | 100.0%               | 100.0%                       | 100.0%                  | 100.0% |
| $X^2$              |     |                      | 8.034                        |                         |        |
| Р                  |     |                      | 0.018                        |                         |        |

Table 7. Comparison between the three studied groups regarding oligohydramnios.

 $X^2$  = Chi square test. *P* was significant if  $\leq$  0.05. N.S., Not significant.

| DET     |     | Group                |                              | Total                   |        |
|---------|-----|----------------------|------------------------------|-------------------------|--------|
| PET     |     | Group A (Heparin gp) | Group B (Aspirin only group) | Group C (Control group) | TOLAT  |
| Absent  | No. | 29                   | 27                           | 49                      | 105    |
|         | %   | 100.0%               | 93.1%                        | 98.0%                   | 97.2%  |
| Present | No. | 0                    | 2                            | 1                       | 3      |
|         | %   | 0.0%                 | 6.9%                         | 2.0%                    | 2.8%   |
| Total   | No. | 29                   | 29                           | 50                      | 108    |
|         | %   | 100.0%               | 100.0%                       | 100.0%                  | 100.0% |
| $X^2$   |     |                      | 2.762                        |                         |        |
| Р       |     |                      | 0.251                        |                         |        |

Table & Comparison between the three studied groups regarding PFT

 $X^2$  = Chi square test. *P* was significant if  $\leq$  0.05. N.S., Not significant.

Other researchers conducted a retrospective study between January 2005 and July 2010 on 64 patients using lowdose LMWH (Enoxaparine 40 mg) from the beginning of pregnancy until 36 weeks of gestation. Their aim was to investigate women with thrombophilia who used LMWH during the 18-22-week period of gestation in comparison to a control group. They found that LMWH did not influence uterine artery or umbilical artery flow velocity [22].

These studies investigated only patients with thrombophilia who have decreased fibrinolytic activity, which leads to a reduction of the trophoblast's ability to invade the endometrium and thus compromise successful placentation. The underlying hypothesis is that thrombophilia mediated by the physiologic hyperestrogenemia of pregnancy synergistic with a genetic thrombophilia pattern promotes thrombus formation in the spiral arteries of the placenta resulting in placental insufficiency and increased pregnancy complications [23].

LMWH may have favorable effects through pathways that have nothing to do with anti-coagulation. Unfractionated heparin and LMWH promote the differentiation and invasion of extravillous trophoblast cells [24, 25] and decrease vascular resistance [26–28]. It has been reported that LMWH is associated with increased heparin-binding epidermal growth factor (HBEGF) protein expression and secretion [24, 29]. HBEGF is a member of the epidermal growth factor (EGF) family, which includes proteins that bind to tyrosine kinase receptors of the human EGF receptor (ERBB) family [30]. HBEGF specifically binds to ERBB1 and ERBB4, but is capable of activating ERBB2 through receptor transactivation [31]. Heparin is a cofactor for proteins with heparin-binding domains, including HBEGF [30]. In addition to HBEGF, heparin is required as a cofactor for fibroblast growth factor (FGF) 4 in the maintenance of rodent trophoblast stem cells [32]. In humans, cytotrophoblasts (CTBs) proliferate in response to heparin and FGF treatment [33]. These studies demonstrated that heparin can activate numerous signaling pathways that could influence trophoblast survival and function.

HBEGF contributes to trophoblast survival and extravillous differentiation during early pregnancy and is dysregulated in placental insufficiencies [24, 34-36]. HBEGF is secreted from trophoblast cells of the human blastocyst [37]. HBGEF induces trophoblast extravillous differentiation [38], regulates endometrial stromal cell motility at the implantation site [39] and provides cytoprotection in an adverse environment [40]. Inhibition of HBEGF signaling by a specific antagonist or by inhibiting ERBB receptors, abrogates its cytoprotective function, as does removal of its cofactor heparan sulfate from the cell surface [41]. HBEGF expression is significantly reduced in all trophoblast populations of placentas from women with preeclampsia [36], supporting a contribution of this deficiency to the associated cell death and poor invasion of those cells. LMWH induces a significant increase in HBEGF protein expression and secretionand reduces TNF- $\alpha$ -induced apoptosis [29].

| IUGR    |     | Group                |                              |                         |        |  |
|---------|-----|----------------------|------------------------------|-------------------------|--------|--|
|         |     | Group A (Heparin gp) | Group B (Aspirin only group) | Group C (Control group) | Total  |  |
| Absent  | No. | 28                   | 26                           | 49                      | 103    |  |
|         | %   | 96.6%                | 89.7%                        | 98.0%                   | 95.4%  |  |
| Present | No. | 1                    | 3                            | 0                       | 4      |  |
|         | %   | 3.4%                 | 10.3%                        | 0.0%                    | 3.7%   |  |
| Total   | No. | 29                   | 29                           | 50                      | 108    |  |
|         | %   | 100.0%               | 100.0%                       | 100.0%                  | 100.0% |  |
| $X^2$   |     |                      | 3.02                         |                         |        |  |
| Р       |     |                      | 0.221                        |                         |        |  |

 $\mathrm{X}^2$  = Chi square test. P was significant if  $\leq$  0.05. N.S., Not significant.

| PTL     |     | Group                |                              |                         |        |  |
|---------|-----|----------------------|------------------------------|-------------------------|--------|--|
| FIL     |     | Group A (Heparin gp) | Group B (Aspirin only group) | Group C (Control group) | Total  |  |
| Absent  | No. | 28                   | 26                           | 50                      | 104    |  |
|         | %   | 96.6%                | 89.7%                        | 100.0%                  | 96.3%  |  |
| Present | No. | 1                    | 3                            | 0                       | 4      |  |
|         | %   | 3.4%                 | 10.3%                        | 0.0%                    | 3.7%   |  |
| Total   | No. | 29                   | 29                           | 50                      | 108    |  |
|         | %   | 100.0%               | 100.0%                       | 100.0%                  | 100.0% |  |
| $X^2$   |     |                      | 5.515                        |                         |        |  |
| Р       |     |                      | 0.063                        |                         |        |  |

 $\mathrm{X}^2$  = Chi square test. P was significant if  $\leq$  0.05. N.S., Not significant.

Table 11. Comparison between the three studied groups regarding NICU admission.

| NICU admission |     | Group                |                              |                         | Total  |
|----------------|-----|----------------------|------------------------------|-------------------------|--------|
|                |     | Group A (Heparin gp) | Group B (Aspirin only group) | Group C (Control group) | TOTAL  |
| Absent         | No. | 28                   | 29                           | 50                      | 107    |
| Absent         | %   | 96.6%                | 100.0%                       | 100.0%                  | 99.1%  |
| Durant         | No. | 1                    | 2                            | 0                       | 3      |
| Present        | %   | 3.4%                 | 6.9%                         | 0.0%                    | 2.8%   |
| Total          | No. | 29                   | 29                           | 50                      | 108    |
| I otal         | %   | 100.0%               | 100.0%                       | 100.0%                  | 100.0% |
| $\mathbf{X}^2$ |     |                      | 2.750                        |                         |        |
| Р              |     |                      | 0.253                        |                         |        |

It is unclear which of these attributes, if any, are key to improving pregnancy outcomes in women with placental insufficiency.

Multiple trials and systematic reviews have concluded that LMWH reduces the incidence of recurrent severe preeclampsia in high-risk women, as well as perinatal mortality, preterm birth, and increased infant birth weight [42, 43].

Despite the fact that we did not find statistically significant differences in fetal growth, fetal cerebral flow velocities, pre-eclampsia, IUGR or preterm labor, there remains a benefit of adding LMWH to protect the fetus against diminished cerebral blood flow in this specific population as we had only abnormal cases of diminished cerebral blood flow in the group treated with aspirin which implies that the combination treatment of LMWH and aspirin reduced the risk of occurrence of hypoxic ischemic encephalopathy. Our results might be promising but our sample was small which made our study under-powered with a low probability of detecting an effect of practical importance. It should act as evidence for a second study to be performed with bigger sample size.

# 6. Conclusions

This study has focused on flow velocities of the uterine arteries and umbilical artery in a population with a history of placental vascular complication in a previous pregnancy. We found that treatment with LMWH influenced uterine artery and umbilical Doppler measurements and the amount of amniotic fluid during the third trimester and reduced the risk of occurrence of hypoxic ischemic encephalopathy in the new born.

# Author contributions

EAAEF: designed, performed the research and wrote the manuscript.

# Ethics approval and consent to participate

The study was approved by Alexandria faculty of medicine ethics committee, trial registeration number 00298/2018, date of registeration 25th of January 2018. Informed Consent was signed by all participants.

# Acknowledgment

Special thanks to doctor El- sayed Amr for his cooperation in statistics, and to nursing staff of the Antenatal care clinic of El- shatby hospital.

## Funding

This research received no external funding.

## **Conflict of interest**

The authors declare no conflict of interest.

## References

- [1] Wallace AE, Host AJ, Whitley GS, Cartwright JE. Decidual natural killer cell interactions with trophoblasts are impaired in pregnancies at increased risk of preeclampsia. The American Journal of Pathology. 2013; 183: 1853–1861.
- [2] Wallace AE, Whitley GS, Thilaganathan B, Cartwright JE. Decidual natural killer cell receptor expression is altered in pregnancies with impaired vascular remodeling and a higher risk of preeclampsia. Journal of Leukocyte Biology. 2015; 97: 79–86.
- [3] Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. American Journal of Obstetrics and Gynecology. 2011; 204: 193–201.
- [4] Carbillon L, Challier JC, Alouini S, Uzan M, Uzan S. Uteroplacental circulation development: Doppler assessment and clinical importance. Placenta. 2001; 22: 795–799.
- [5] Ridding G, Schluter PJ, Hyett JA, McLennan AC. Uterine artery pulsatility index assessment at 11–13 weeks' gestation. Fetal Diagnosis and Therapy. 2014; 36: 299–304.
- [6] Alves JAG, Silva BYDC, de Sousa PCP, Maia SB, Costa FDS. Reference range of uterine artery Doppler parameters between the 11th and 14th pregnancy weeks in a population sample from Northeast Brazil. Revista Brasileira de Ginecologia e Obstetrícia. 2013; 35: 357–362.
- [7] Lefebvre J, Demers S, Bujold E, Nicolaides KH, Girard M, Brassard N, et al. Comparison of two different sites of measurement for transabdominal uterine artery Doppler velocimetry at 11–13 weeks. Ultrasound in Obstetrics & Gynecology. 2012; 40: 288– 292.
- [8] Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertility and Sterility. 2006; 86: 362–366.
- [9] Venkat-Raman N, Backos M, Teoh TG, Lo WT, Regan L. Uterine artery Doppler in predicting pregnancy outcome in women with antiphospholipid syndrome. Obstetrics & Gynecology. 2001; 98: 235–242.
- [10] Gómez O, Figueras F, Fernández S, Bennasar M, Martínez JM, Puerto B, et al. Reference ranges for uterine artery mean pulsatility index at 11–41 weeks of gestation. Ultrasound in Obstetrics & Gynecology. 2008; 32: 128–132.

- [11] Peixoto AB, Da Cunha Caldas TMR, Tonni G, De Almeida Morelli P, Santos LD, Martins WP, et al. Reference range for uterine artery Doppler pulsatility index using transvaginal ultrasound at 20-24w6d of gestation in a low-risk Brazilian population. Journal of the Turkish German Gynecological Association. 2016; 17: 16– 20.
- [12] Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements-a prospective study. American Journal of Obstetrics and Gynecology. 1985; 151: 333–337.
- [13] Magann EF, Chauhan SP, Washington W, Whitworth NS, Martin JN, Morrison JC. Ultrasound estimation of amniotic fluid volume using the largest vertical pocket containing umbilical cord: measure to or through the cord? Ultrasound in Obstetrics & Gynecology. 2002; 20: 464–467.
- [14] Phelan JP, Smith CV, Broussard P, Small M. Amniotic fluid volume assessment with the four-quadrant technique at 36–42 weeks' gestation. The Journal of Reproductive Medicine. 1987; 32: 540– 542.
- [15] Phelan JP, Park YW, Ahn MO, Rutherford SE. Polyhydramnios and perinatal outcome. Journal of Perinatology. 1990; 10: 347– 350.
- [16] Rutherford SE, Phelan JP, Smith CV, Jacobs N. The four-quadrant assessment of amniotic fluid volume: an adjunct to antepartum fetal heart rate testing. Obstetrics and Gynecology. 1987; 70: 353– 356.
- [17] Brown MA, Lindheimer MD, de Swiet M, Assche AV, Moutquin J. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertension in Pregnancy. 2001; 20: IX–XIV.
- [18] Soothill PW, Bobrow CS, Holmes R. Small for gestational age is not a diagnosis. Ultrasound in Obstetrics and Gynecology. 1999; 13: 225–228.
- [19] Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to heparin. Obstetrics and Gynecology. 2011; 117: 1375–1383.
- [20] Torricelli M, Reis FM, Florio P, Severi FM, Bocchi C, Picciolini E, et al. Low-molecular-weight heparin improves the performance of uterine artery Doppler velocimetry to predict preeclampsia and small-for-gestational age infant in women with gestational hypertension. Ultrasound in Medicine & Biology. 2006; 32: 1431–1435.
- [21] Abheiden C, Van Hoorn M, Hague W, Kostense P, van Pampus M, de Vries J. Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG: an International Journal of Obstetrics & Gynaecology. 2015; 123: 797–805.
- [22] Cok T, Tarim E, Iskender C. Comparison of uterine artery Doppler in pregnant women with thrombophilia treated by LMWHs and without thrombophilia. Archives of Gynecology and Obstetrics. 2012; 286: 575–579.
- [23] Paidas MJ, Ku DW, Arkel YS. Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome. Clinics in Perinatology. 2004; 31: 783–805.
- [24] Chen Y, Wu X, Tan J, Liu M, Liu Y, Zhang J. Effects of low molecular weight heparin and heparin-binding epidermal growth factor on human trophoblast in first trimester. Fertility and Sterility. 2012; 97: 764–770.
- [25] D'Ippolito S, Di Nicuolo F, Marana R, Castellani R, Stinson J, Tersigni C, et al. Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression. Fertility and Sterility. 2012; 98: 1028–1036.
- [26] Ganapathy R, Whitley GSJ, Cartwright JE, Dash PR, Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Human Reproduction. 2007; 22: 2523–2527.

- [27] Hills FA, Abrahams VM, González-Timón B, Francis J, Cloke B, Hinkson L, et al. Heparin prevents programmed cell death in human trophoblast. Molecular Human Reproduction. 2006; 12: 237– 243.
- [28] Oberkersch R, Attorresi AI, Calabrese GC. Low-molecularweight heparin inhibition in classical complement activation pathway during pregnancy. Thrombosis Research. 2010; 125: e240– e245.
- [29] Di Simone N, Di Nicuolo F, Sanguinetti M, Ferrazzani S, D'Alessio MC, Castellani R, et al. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta. 2007; 28: 298–304.
- [30] Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology. 1998; 20: 41–48.
- [31] Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annual Review of Pharmacology and Toxicology. 2004; 44: 195–217.
- [32] Tanaka S, Kunath T, Hadjantonakis AK, Nagy A, Rossant J. Promotion of trophoblast stem cell proliferation by FGF4. Science. 1998; 282: 2072–2075.
- [33] Baczyk D, Dunk C, Huppertz B, Maxwell C, Reister F, Giannoulias D, et al. Bi-potential behaviour of cytotrophoblasts in first trimester chorionic villi. Placenta. 2006; 27: 367–374.
- [34] Chobotova K, Karpovich N, Carver J, Manek S, Gullick WJ, Barlow DH, et al. Heparin-binding epidermal growth factor and its receptors mediate decidualization and potentiate survival of human endometrial stromal cells. The Journal of Clinical Endocrinology and Metabolism. 2005; 90: 913–919.
- [35] Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. The Cochrane

Database of Systematic Reviews. 2013; CD006780.

- [36] Leach RE, Romero R, Kim YM, Chaiworapongsa T, Kilburn B, Das SK, et al. Pre-eclampsia and expression of heparin-binding EGF-like growth factor. The Lancet. 2002; 360: 1215–1219.
- [37] Aghajanova L, Shen S, Rojas AM, Fisher SJ, Irwin JC, Giudice LC. Comparative transcriptome analysis of human trophectoderm and embryonic stem cell-derived trophoblasts reveal key participants in early implantation. Biology of Reproduction. 2012; 86: 1–21.
- [38] Leach RE, Kilburn B, Wang J, Liu Z, Romero R, Armant DR. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Developmental Biology. 2004; 266: 223–237.
- [39] Schwenke M, Knöfler M, Velicky P, Weimar CHE, Kruse M, Samalecos A, et al. Control of human endometrial stromal cell motility by PDGF-BB, HB-EGF and trophoblast-secreted factors. PLoS ONE. 2013; 8: e54336.
- [40] Jessmon P, Kilburn BA, Romero R, Leach RE, Armant DR. Function-specific intracellular signaling pathways downstream of heparin-binding EGF-like growth factor utilized by human trophoblasts. Biology of Reproduction. 2010; 82: 921–929.
- [41] Armant DR. Human trophoblast survival at low oxygen concentrations requires metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor. Development. 2006; 133: 751-759.
- [42] McLaughlin K, Drewlo S, Parker JD, Kingdom JCP. Current theories on the prevention of severe preeclampsia with low-molecular weight heparin. Hypertension. 2015; 66: 1098–1103.
- [43] Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014; 123: 822–828.